Celadon Pharmaceuticals focuses on delivering solutions where traditional medicine often fails. The company is poised for accelerated growth by capitalizing on this specialized market.
The specialized pharmaceutical market is expected to reach £37 billion by 2027.
Celadon operates within a highly regulated space that currently includes only around 12 companies, providing a competitive advantage.
The company has multiple revenue streams ready for deployment, including income from pharmaceutical product sales, data commercialization, and IP licensing. The use of funds is specifically focused on revenue generation
Key Market Drivers
- The Convertible Loan Note offers investors a dependable income stream with a 10% per annum interest rate over a 4-year term.
- Additionally, the Note provides equity upside via a conversion option at a 20% discount to ordinary shares. The maximum principal raised is £20,000,000
